Lymphoid interstitial pneumonia in Sjögren disease: clinical course and comparison with other interstitial lung disease patterns
Clicks: 4
ID: 318201
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
0.9
/100
4 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #14 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives Lymphoid interstitial pneumonia (LIP) is a rare form of Interstitial Lung Disease (ILD), often associated with Sjögren Disease (SjD). However, the clinical-serologic characteristics of SjD-LIP remain poorly characterized. Our objective was to describe the clinical course and outcome of SjD-associated LIP and to compare this subgroup with other SjD-ILD patterns. Methods SjD patients with HRCT-confirmed ILD followed in Pisa Rheumatology Unit (January 2019–November 2024) were retrospectively enrolled. ILD patterns were classified through multidisciplinary discussion. Clinical and laboratory data were collected according to ESSDAI definitions, along with pulmonary symptoms and function tests (PFTs). Results Fifty-five SjD-ILD patients were included (M: F = 9:46), of whom 11 were diagnosed with LIP (F: M = 11:0). LIP patients showed thin-walled parenchymal cysts as the predominant HRCT finding, and largely preserved pulmonary function (median FVC 101% [IQR 98–105]; DLCO 76% [IQR 75–81]). After a median 5-years follow-up (IQR 2–7) all LIP patients were alive with stable PFTs. Compared with the remaining 44 non-LIP, LIP patients were younger at SjD diagnosis (p<0.001) and more frequently presented purpura (p=0.012), constitutional symptoms (p=0.001), lymphadenopathy (p=0.023), hypergammaglobulinemia (p<0.001), triple anti-Ro60/52/La positivity (p=0.035) and C3 hypocomplementemia (p=0.009). ILD preceded SjD diagnosis in 30/44 non-LIP vs 1/11 LIP patients (p<0.001), with lower FVC% (p=0.049) and DLCO% (p=0.036) in non-LIP. Conclusion LIP defines a distinct, immunologically active phenotype within the spectrum of SjD-ILD, characterized by greater extrapulmonary systemic involvement and serologic markers of B cell hyperactivity, but limited pulmonary functional impact. These findings support long-term lymphoma surveillance and a potential role for B cell targeted therapies in selected patients.
| Reference Key |
openalex_W7165525163
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Gaetano La Rocca, Francesco Ferro, Vincenzo Uggenti, B. Dei, Giovanni Fulvio, Michele Moretti, Riccardo Morganti, Gianluca Sambataro, Marta Mosca, Chiara Romei, Chiara Baldini |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag321
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.